Volume 15, Number 6—June 2009
Escherichia coli and Klebsiella pneumoniae Carbapenemase in Long-term Care Facility, Illinois, USA
To the Editor: Escherichia coli harboring Klebsiella pneumoniae carbapenemases (KPCs) are now rarely being reported. Worldwide, KPC-2 has been detected in Israel and the People’s Republic of China (1,2). Within the United States, carbapenem-resistant E. coli carrying blaKPC has been isolated in New Jersey (3) and Cleveland, Ohio (4), and 7 carbapenem-resistant E. coli isolates were obtained from 3 different hospitals in Brooklyn, New York (5). Urban et al. (6) recently reported 9 KPC-2 and KPC-3 carbapenemases in urinary E. coli isolates from 7 long-term care facilities. We report such an isolate from a resident of a long-term care facility.
This case involved a 68-year-old female resident of a long-term care facility in Centralia, Illinois, who had multiple chronic medical problems, including cerebral palsy, a seizure disorder, and recurrent urinary tract infections. A urine culture grew >105 CFU/mL of E. coli susceptible to amikacin, gentamicin, tobramycin, piperacillin/tazobactam, trimethoprim/sulfamethoxazole, imipenem, and nitrofurantoin. Tigecycline susceptibility was not determined. Trimethoprim/sulfamethoxazole therapy was initiated. Follow-up urine culture almost 3 weeks later again grew >105 CFU/mL of E. coli, now susceptible to amikacin, gentamicin, tobramycin, nitrofurantoin, and tigecycline. The isolate was resistant to imipenem and meropenem. A modified Hodge test demonstrated production of a carbapenemase (7), and the blaKPC gene was detected by PCR at the Centers for Disease Control and Prevention (CDC). The patient was treated with a 10-day course of nitrofurantoin, 100 mg by gastrostomy tube 2× per day. Chart review indicated that contact precautions were instituted only after discovery of the second E. coli isolate.
Seventeen days later, a repeat urine culture grew >105 CFU/mL of K. pneumoniae susceptible only to amikacin, gentamicin, tobramycin, and tigecycline. No treatment was given. Follow-up urine culture grew >105 CFU/mL of K. pneumoniae again with a similar resistance pattern. The modified Hodge test result was positive (7) and was confirmed as blaKPC positive by PCR at CDC. The resident was transferred to an acute care facility for further evaluation and was treated with amikacin. At completion of therapy, a repeat urine culture was negative for organisms.
Our case, like that of Urban et al. (6), involved a urinary isolate from a resident of a long-term care facility. As increasing numbers of resistant gram-negative rods colonize such patients, the patients may acquire a bacterium carrying a KPC plasmid conferring broad-spectrum resistance as described in our patient. These plasmids may then be laterally transferred to other gram-negatives, which may have occurred in this case.
Our case underscores the gravity of the evolutionary process of emergent, multidrug–resistant enterobacteriaceae. Even though E. coli strains that harbor carbapenemase genes are not ubiquitous, additional therapeutic interventions are needed to prevent the spread of these bacteria, which are likely to infect increasing numbers of patients.
- Navon-Venezia S, Chmelnitsky I, Leavitt A, Schwaber M, Schwartz D, Carmeli Y. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother. 2006;50:3098–101.
- Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli isolates possessing the plasmid-mediated carbapenem-hydrolyzing β-lactamase KPC-2 in intensive care units of Chinese hospital. Antimicrob Agents Chemother. 2008;52:2014–8.
- Hong T, Moland ES, Abdalhamid B, Hanson ND, Wang J, Sloan C, E. coli producing KPC-3 carapenem hydrolyzing enzyme. In: Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington: American Society for Microbiology; 2003. p. 75. Abstract C1-265.
- Deshpande LM, Rhomberg PR, Sader HS, Jones RN. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacteriaceae isolated in the United States Medical Centers: Report from the MYSTIC Program (1999–2005). Diagn Microbiol Infect Dis. 2006;56:367–72.
- Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D, Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis. 2007;44:972–5.
- Urban C, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W, Grenner L, et al. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase β-lactamases associated with long-term care facilities. Clin Infect Dis. 2008;46:e127–30.
- Anderson KF, Lonsway DR, Rasheed JK, Biddle J, Jensen B, McDougal LK, Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol. 2007;45:2723–5.
Suggested citation for this article: McGuinn M, Hershow RC, Janda WM. Escherichia coli and Klebsiella pneumoniae carbapenemase in long-term care facility, Illinois, USA [letter]. Emerg Infect Dis [serial on the Internet]. 2009 Jun [date cited]. Available from http://wwwnc.cdc.gov/eid/article/15/6/08-1735
Please use the form below to submit correspondence to the authors or contact them at the following address:
Marcella McGuinn, Section of Infectious Diseases (MC 735), Rm 887, College of Medicine East, 808 S Wood St, Chicago, IL 60612, USA
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: December 08, 2010
- Page last updated: December 08, 2010
- Page last reviewed: December 08, 2010
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)